ATEC Alphatec Holdings, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1350653 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY15.3%
TTM net income YoY43.9%
TTM EPS YoY45.2%
Revenue 3-yr CAGR23.1%
Net income 3-yr CAGR—
Margins
Gross margin71.3%
Operating margin-3.6%
Net margin-10.3%
FCF margin0.4%
EBITDA margin4.7%
Returns
ROE-1,888.0%
ROA-11.0%
ROIC (approx.)-5.4%
Asset turnover1.06x
Leverage & solvency
Liabilities / assets97.3%
Debt / equity—
Current ratio2.36x
Interest coverage-0.65x
Cash quality & payout
Operating cash flow / net income-0.71x
Accruals ratio-18.7%
Payout ratio—
Capex / revenue6.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $764.15M | $611.56M | $482.26M | $350.87M | $243.21M |
| Cost of revenue | $232.27M | $187.30M | $172.06M | $117.81M | $85.45M |
| Gross profit | $531.89M | $424.26M | $310.20M | $233.06M | $157.76M |
| R&D expense | $76.27M | $80.72M | $70.11M | $44.03M | $32.02M |
| SG&A expense | $498.53M | $450.20M | $374.08M | $300.01M | $229.27M |
| Operating income | -$82.13M | -$136.17M | -$173.40M | -$146.97M | -$128.06M |
| Interest expense | $45.92M | $24.88M | $16.64M | $5.50M | $7.11M |
| Pretax income | -$143.40M | -$162.07M | -$186.91M | -$152.01M | -$144.16M |
| Income tax | -$45,000 | $50,000 | -$277,000 | -$716,000 | -$1.13M |
| Net income | -$143.36M | -$162.12M | -$186.64M | -$151.29M | -$143.03M |
| EBITDA | -$4.64M | -$57.75M | -$117.26M | -$105.81M | -$101.30M |
| EPS (basic) | -0.96 | -1.13 | -1.54 | -1.46 | -1.49 |
| EPS (diluted) | -0.96 | -1.13 | -1.54 | -1.46 | -1.49 |
| Weighted avg. shares (diluted) | 150.06M | 142.95M | 121.24M | 103.37M | 96.20M |
| Balance sheet | |||||
| Cash & equivalents | $160.81M | $138.84M | $220.97M | $84.70M | $187.25M |
| Receivables | $97.30M | $82.99M | $72.61M | $60.06M | $41.89M |
| Inventory | $169.44M | $175.26M | $136.84M | $101.52M | $91.70M |
| Current assets | $450.88M | $417.40M | $451.09M | $255.63M | $331.16M |
| PP&E, net | $135.32M | $156.39M | $149.84M | $101.95M | $87.40M |
| Goodwill | $75.21M | $70.98M | $73.00M | $47.37M | $39.69M |
| Intangibles | $93.45M | $93.52M | $102.45M | $82.78M | $85.27M |
| Total assets | $791.21M | $775.71M | $805.21M | $520.97M | $572.05M |
| Current liabilities | $219.18M | $153.03M | $157.57M | $138.87M | $101.09M |
| Short-term debt | $64.53M | $1.66M | $1.81M | $14.95M | $342,000 |
| Long-term debt | $501.41M | $574.52M | $511.04M | $349.51M | $326.49M |
| Total debt | $565.94M | $576.18M | $512.84M | $364.46M | $326.83M |
| Total liabilities | $755.18M | $766.28M | $703.49M | $532.03M | $467.78M |
| Shareholders' equity | $12.43M | -$14.17M | $78.12M | -$34.67M | $80.67M |
| Net debt | $405.13M | $437.34M | $291.87M | $279.76M | $139.58M |
| Shares outstanding | 150.26M | 144.13M | 139.25M | 106.64M | 99.54M |
| Cash flow statement | |||||
| Operating cash flow | $45.23M | -$44.65M | -$78.48M | -$75.13M | -$73.32M |
| Capital expenditure | $42.45M | $83.22M | $80.51M | $49.45M | $68.54M |
| Free cash flow | $2.78M | -$127.87M | -$158.99M | -$124.59M | -$141.86M |
| Investing cash flow | -$53.41M | -$93.14M | -$141.97M | -$58.28M | -$157.76M |
| Financing cash flow | $30.02M | $56.21M | $356.92M | $31.23M | $311.97M |
| Depreciation & amortization | $77.49M | $78.42M | $56.14M | $41.17M | $26.76M |
| Stock-based compensation | $73.72M | $73.28M | $81.24M | $40.56M | $36.45M |
| Share buybacks | — | — | — | — | $25.00M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.